与药物相关的严重甲状腺功能低下症后的利多米德再暴露:一个病例报告
Francesca Bartolomei1, Tommaso Za1, Francesca Di Landro1
1Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Annals of hematology
|February 20, 2026
概括
用于多发性骨髓瘤 (MM) 的波马利多米德可以导致甲状腺功能低下症. 建议对甲状腺功能进行监测,在治疗甲状腺功能低下后,重新使用利多米德是安全的.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 波马利多米德是一种有效的口服治疗复发性耐火性多发性骨髓瘤 (MM).
- 它通常耐受良好,即使在老年患者中也是如此.
- 药物诱导的甲状腺功能低下是一种潜在的不良影响.
研究的目的:
- 在多发性骨髓瘤患者中报告马利多米德诱导的严重甲状腺功能低下病例.
- 评估在甲状腺功能低下症治疗后重新使用波马利多米德的安全性.
主要方法:
- 一个71岁妇女的案例研究,患有复发性/耐药的MM,接受了玛利多米德治疗.
- 在治疗前和治疗期间监测甲状腺功能.
- 开始用于甲状腺功能低下症的levothyroxine治疗.
- 在实现甲状腺功能减退后,用pomalidomide重新挑战.
主要成果:
- 患者在利多米德治疗期间出现严重的甲状腺功能低下症.
- 莱沃甲状腺素治疗迅速解决了她的症状.
- 用波马利多米德重新挑战是安全的,对甲状腺功能没有不良影响.
结论:
- 波马利多米德可以诱导多发性骨髓瘤患者的甲状腺功能低下症.
- 在利多米德治疗期间,定期进行甲状腺功能检测至关重要.
- 在成功治疗甲状腺功能低下症后,使用波马利多米德重新挑战是一种安全的选择.
相关概念视频
Drug toxicity: Idiosyncratic Reactions
45
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
45
Drug Toxicity: Allergic Reactions
36
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
36
Drug Toxicity: Risk factors
38
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
38
Drug Toxicity: Dose-Dependent Reactions
35
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
35
Hypersensitivity Reactions: Cytolytic Reactions
43
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
43
Hypersensitivity Reactions: Immune-Complex Reactions
40
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
40


